3.71
Schlusskurs vom Vortag:
$3.71
Offen:
$3.75
24-Stunden-Volumen:
7.07M
Relative Volume:
1.21
Marktkapitalisierung:
$1.27B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.80M
KGV:
-10.60
EPS:
-0.35
Netto-Cashflow:
$-68.07M
1W Leistung:
+15.94%
1M Leistung:
+17.78%
6M Leistung:
+123.49%
1J Leistung:
+58.55%
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
(415) 754-3517
Adresse
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Vergleichen Sie NUVB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NUVB
Nuvation Bio Inc
|
3.71 | 1.27B | 0 | -75.80M | -68.07M | -0.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-30 | Eingeleitet | Jefferies | Buy |
2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
2021-10-15 | Fortgesetzt | BTIG Research | Buy |
2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
2021-03-08 | Eingeleitet | BTIG Research | Buy |
2021-03-08 | Eingeleitet | Cowen | Outperform |
2021-03-08 | Eingeleitet | Jefferies | Buy |
2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Is Nuvation Bio Inc. Warrants stock undervalued after correctionMarket Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Can Nuvation Bio Inc. Class stock resist broad market declinesMarket Activity Report & Safe Entry Momentum Tips - newser.com
Is Nuvation Bio Inc. stock resilient to inflationWeekly Stock Report & Fast Gaining Stock Reports - newser.com
Will Nuvation Bio Inc. Class stock top growth indexesBond Market & Capital Efficient Trading Techniques - newser.com
Is Nuvation Bio Inc. reversing from oversold territoryJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Will Nuvation Bio Inc. Warrants stock sustain uptrend momentumMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Custom watchlist performance reports with Nuvation Bio Inc.Earnings Growth Summary & Stepwise Swing Trade Plans - newser.com
How big funds are accumulating Nuvation Bio Inc. Warrants stockGlobal Markets & Technical Buy Zone Confirmations - newser.com
Nuvation Bio Inc. stock retracement – recovery analysis2025 Risk Factors & Daily Profit Maximizing Tips - newser.com
How Nuvation Bio Inc. Class stock moves in volatile trading sessionsOptions Play & Real-Time Volume Trigger Notifications - newser.com
Will Nuvation Bio Inc. stock continue dividend increasesMarket Growth Review & Low Drawdown Investment Ideas - newser.com
How moving averages guide Nuvation Bio Inc. tradingMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
Assessing Nuvation Bio (NUVB) Valuation After Recent Share Price Momentum in the Biotech Sector - Yahoo
Nuvation Bio Hits Day High with 15.63% Surge in Strong Intraday Performance - Markets Mojo
Multi factor analysis applied to Nuvation Bio Inc.Market Movers & Accurate Intraday Trade Tips - newser.com
Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment - MSN
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Investing News Network
Jefferies initiates Nuvation Bio stock with Buy rating, $10 price target - Investing.com Nigeria
Why Nuvation Bio Stock Is Skyrocketing Today - Mitrade
Nuvation Bio Shares Rise After First Patient Enrolled in Phase 3 Lung Cancer Drug Trial - MarketScreener
Nuvation issues trial update as Jefferies says buy (NUVB) - Seeking Alpha
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
Jefferies Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation - Nasdaq
Nuvation Bio enrolls first patient in phase 3 lung cancer trial - Investing.com
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Business Wire
What market sentiment indicators show for Nuvation Bio Inc. Class stockProduct Launch & Low Risk Investment Opportunities - newser.com
3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
Will breakout in Nuvation Bio Inc. lead to full recoveryMarket Weekly Review & Verified Entry Point Signals - newser.com
Why Nuvation Bio Inc. stock is popular among millennials2025 Valuation Update & High Accuracy Trade Alerts - newser.com
Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer - StocksToTrade
Nuvation Bio (NUVB) Surges Amid Major Regulatory Milestone in Japan - timothysykes.com
What analysts say about Nuvation Bio Inc stockMorning Star Patterns & Discover Strategies with Fellow Traders - earlytimes.in
Nuvation Bio Soars As Japan Approves Ibtrozi for Advanced Lung Cancer - StocksToTrade
Nuvation Bio Stock Hits Day Low of $3.00 Amid Price Pressure - Markets Mojo
Nuvation Bio (NYSE:NUVB) Stock Price Up 7.2%Here's Why - MarketBeat
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):